• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

    7/24/24 4:15:09 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    5AM Partners VI, LLC

    (Last) (First) (Middle)
    4 EMBARCADERO CENTER, SUITE 3110

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Artiva Biotherapeutics, Inc. [ ARTV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/22/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/22/2024 C 1,058,284 A (1) 1,058,284 I By 5AM Ventures VI, L.P.(2)
    Common Stock 07/22/2024 J(3) 112,966 A $10.2 1,171,250 I By 5AM Ventures VI, L.P.(2)
    Common Stock 07/22/2024 J(4) 348,721 A $10.2 348,721 I By 5AM Opportunities II, L.P.(5)
    Common Stock 07/22/2024 P 833,333 A $12 1,182,054 I By 5AM Opportunities II, L.P.(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A Preferred Stock (1) 07/22/2024 C 843,592 (1) (1) Common Stock 843,592 (1) 0 I By 5AM Ventures VI, L.P.(2)
    Series B Preferred Stock (1) 07/22/2024 C 214,692 (1) (1) Common Stock 214,692 (1) 0 I By 5AM Ventures VI, L.P.(2)
    1. Name and Address of Reporting Person*
    5AM Partners VI, LLC

    (Last) (First) (Middle)
    4 EMBARCADERO CENTER, SUITE 3110

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    5AM Ventures VI, L.P.

    (Last) (First) (Middle)
    4 EMBARCADERO CENTER, SUITE 3110

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    5AM Opportunities II (GP), LLC

    (Last) (First) (Middle)
    4 EMBARCADERO CENTER, SUITE 3110

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    5AM Opportunities II, L.P.

    (Last) (First) (Middle)
    4 EMBARCADERO CENTER, SUITE 3110

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    PARMAR KUSH

    (Last) (First) (Middle)
    C/O 5AM VENTURE MANAGEMENT, LLC
    4 EMBARCADERO CENTER, SUITE 3110

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Schwab Andrew J.

    (Last) (First) (Middle)
    C/O 5AM VENTURE MANAGEMENT, LLC
    4 EMBARCADERO CENTER, SUITE 3110

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
    2. The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.
    3. Represents the conversion of outstanding simple agreement for future equity in the amount of $1,152,253.93 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
    4. Represents the conversion of outstanding simple agreement for future equity in the amount of $3,556,957.78 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
    5. Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.
    5AM Partners VI, LLC, By /s/ Kush Parmar, Managing Member 07/24/2024
    5AM Ventures VI, L.P., By: 5AM Partners VI, LLC, its General Partner, By /s/ Kush Parmar, Managing Member 07/24/2024
    5AM Opportunities II (GP), LLC, By /s/ Kush Parmar, Managing Member 07/24/2024
    5AM Opportunities II, L.P., By: 5AM Opportunities II (GP), LLC, its General Partner, By /s/ Kush Parmar, Managing Member 07/24/2024
    /s/ Kush Parmar 07/24/2024
    /s/ Andrew J. Schwab 07/24/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ARTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gc Corp. bought $16,499,992 worth of shares (1,432,291 units at $11.52) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/28/26 4:34:23 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, Research and Development Raymon Heather sold $27,879 worth of shares (3,095 units at $9.01), decreasing direct ownership by 2% to 148,228 units (SEC Form 4) to satisfy withholding tax

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/19/26 9:52:54 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Tech Operations Officer Horan Christopher sold $63,073 worth of shares (7,002 units at $9.01), decreasing direct ownership by 2% to 293,450 units (SEC Form 4) (for withholding tax)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/19/26 9:52:09 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The $13 Million Company Teaching the Immune System to Hunt Cancer

    Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep

    5/29/26 9:00:00 AM ET
    $ARTV
    $FATE
    $GTBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

    SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website. The archived audio webcast will remain available for replay on Artiva's website for 90 days. About Arti

    5/28/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

    Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up with no patients relapsing or requiring new immunomodulatory agentsOral presentation to feature positive experience in the first patient with severe Sjögren disease treated with AlloNK + rituximabPoster presentations to highlight deep, consistent B-cell depletion comparable to CD19 CAR T-cell therapies and a favorable safety profile in immune-mediated diseasesLive post-meeting webcast to be held Monday, June 8

    5/19/26 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gc Corp. bought $16,499,992 worth of shares (1,432,291 units at $11.52) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/28/26 4:34:23 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. bought $74,999,992 worth of shares (6,510,416 units at $11.52) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/13/26 5:45:56 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/24/24 4:27:11 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    SEC Filings

    View All

    SEC Form 8-K filed by Artiva Biotherapeutics Inc.

    8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    5/19/26 8:07:26 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Artiva Biotherapeutics Inc.

    144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    5/18/26 7:53:05 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Artiva Biotherapeutics Inc.

    144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    5/18/26 7:51:16 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

    6/11/25 7:52:47 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

    12/30/24 7:13:58 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

    Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

    8/13/24 7:24:03 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Leadership Updates

    Live Leadership Updates

    View All

    Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

    Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from discovery through FDA approval and commercialization, including PREZISTA® and INTELENCE® SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings

    5/19/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

    SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. "We are delighted to welcome Thad to Artiva as he brings strong late-stage development and comme

    2/24/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

    SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis. "We are thrilled to welcome Elaine to Artiva's board at such an imp

    2/19/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

    SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    11/14/24 4:56:18 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

    SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    9/3/24 4:18:05 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

    SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    8/1/24 7:00:07 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care